Myriad Genetics MYGN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $829M+0.5% | $824.5M-0.1% | $825.3M-0.9% | $832.9M+0.2% | $831.3M-0.8% | ||
| $249M+0.4% | $247.9M+1.3% | $244.6M-0.6% | $246.2M-1.2% | $249.3M-1.1% | ||
| $580M+0.6% | $576.6M-0.7% | $580.7M-1.0% | $586.7M+0.8% | $582M-0.6% | ||
| 70%0.0pp | 69.9%-0.4pp | 70.4%-0.1pp | 70.4%+0.4pp | 70%+0.1pp | ||
| $106.4M-0.4% | $106.8M-5.9% | $113.5M-0.3% | $113.8M-1.3% | $115.3M+2.3% | ||
| $285.2M+1.6% | $280.8M-1.2% | $284.1M+0.4% | $283M-0.3% | $283.9M-0.1% | ||
| $252.5M-1.7% | $256.8M-3.2% | $265.2M-0.5% | $266.5M-1.9% | $271.8M-1.7% | ||
| $968.9M+0.5% | $963.8M-3.7% | $1B-0.3% | $1B+42.1% | $706.5M-0.3% | ||
| $968.9M+0.5% | $963.8M-3.7% | $1B-0.3% | $1B+42.1% | $706.5M-0.3% | ||
| -$388.9M-0.4% | -$387.2M+7.9% | -$420.5M-0.8% | -$417.2M-235% | -$124.5M-0.9% | ||
| -46.9%0.0pp | -47%+4.0pp | -51%-0.9pp | -50.1%-35.1pp | -15%-0.2pp | ||
| $13.8M+31.4% | $10.5M+54.4% | $6.8M+78.9% | $3.8M+22.6% | $3.1M+10.7% | ||
| $2.2M+22.2% | $1.8M+38.5% | $1.3M+8.3% | $1.2M-14.3% | $1.4M-17.6% | ||
| -$10.9M-38.0% | -$7.9M-64.6% | -$4.8M-54.8% | -$3.1M-29.2% | -$2.4M— | ||
| -$399.8M-1.2% | -$395.1M+7.1% | -$425.3M-1.2% | -$420.3M-231% | -$126.9M-2.8% | ||
| $100K+100% | -$29.2M-17.7% | -$24.8M+1.2% | -$25.1M+1.6% | -$25.5M-754% | ||
| -$399.9M-9.3% | -$365.9M+8.6% | -$400.5M-1.3% | -$395.2M-290% | -$101.4M+20.3% | ||
| -48.2%-3.9pp | -44.4%+4.1pp | -48.5%-1.1pp | -47.4%-35.3pp | -12.2%+3.0pp | ||
| -$4.29-9.2% | -$3.93+9.2% | -$4.33-1.2% | -$4.28-282% | -$1.12+20.6% | ||
| -$4.29-9.2% | -$3.93+9.2% | -$4.33-1.2% | -$4.28-282% | -$1.12+20.6% | ||
| 371.9M+0.6% | 369.6M+0.5% | 367.6M+0.6% | 365.4M+0.5% | 363.5M+0.4% | ||
| 371.9M+0.6% | 369.6M+0.5% | 367.6M+0.6% | 365.4M+0.5% | 363.5M+0.4% | ||
| —— | $0+100% | -$5.33M+50.0% | -$10.65M+33.3% | -$15.98M+25.0% | ||
| $700K-12.5% | $800K+14.3% | $700K+240% | -$500K+28.6% | -$700K-164% | ||
| $829M+0.5% | $824.5M-0.1% | $825.3M-0.9% | $832.9M+0.2% | $831.3M-0.8% | ||
| $32.2M-8.5% | $35.2M-18.7% | $43.3M-0.5% | $43.5M-8.0% | $47.3M-5.0% | ||
| -$388.9M-0.4% | -$387.2M+7.9% | -$420.5M-0.8% | -$417.2M-235% | -$124.5M-0.9% | ||
| -$337.1M-1.1% | -$333.5M+8.5% | -$364.6M-1.8% | -$358.3M-455% | -$64.6M-3.9% | ||
| -$337.1M-1.1% | -$333.5M+8.5% | -$364.6M-1.8% | -$358.3M-455% | -$64.6M-3.9% | ||
| -40.7%-0.2pp | -40.4%+3.7pp | -44.2%-1.2pp | -43%-35.2pp | -7.8%-0.3pp | ||
| -$388.9M-0.4% | -$387.2M+7.9% | -$420.5M-0.8% | -$417.2M-235% | -$124.5M-0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Myriad Genetics's revenue?
- Myriad Genetics (MYGN) generated $829.0M in revenue over the trailing twelve months, down 0.3% year over year.
- Is Myriad Genetics profitable?
- Myriad Genetics is not currently profitable: it reported a net loss of $399.9M over the trailing twelve months, a -48.2% net margin.
- What are Myriad Genetics's profit margins?
- Gross margin is 70.0% and operating margin is -46.9%, with a -48.2% net margin.
- What is Myriad Genetics's earnings per share?
- Myriad Genetics's diluted EPS over the trailing twelve months is $-4.29.
- Where does Myriad Genetics's income statement data come from?
- Every line is extracted from Myriad Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
